Coverage for Wegovy and Zepbound tightens as costs strain insurers, patients

Insurers and employers are pulling back on coverage for Wegovy and Zepbound just as demand for the obesity drugs keeps climbing, leaving millions of patients facing higher costs, fresh paperwork or a forced stop in treatment. GoodRx said 12 million people lost coverage for Zepbound over the last year, and the same number lost coverage for Wegovy, a sign that access is narrowing even as the medicines have become central to obesity care.

GoodRx’s March 31 analysis found that the number of people with no commercial insurance coverage for Wegovy rose 42% from 2025 to more than 41 million. The number with no coverage for Zepbound rose 12% to more than 109 million. Even when plans do cover GLP-1 and GIP drugs for weight loss, more than 88% still require extra steps such as prior authorization. More than 16 million people lack commercial insurance coverage for any GIP or GLP-1 agonist prescribed for weight loss.

The practical effect is blunt: patients who had started treatment may have to switch drugs, pay full price, or abandon therapy altogether. That matters because the medications cost around $1,000 a month or more and are meant for long-term use, not short bursts. Penn LDI said insurers have responded to that expense by raising cost-sharing and leaning harder on prior authorization to control use.

Coverage remains especially uneven in the individual market. KFF found that Wegovy, which is approved for obesity treatment, was covered by just 1% of ACA Marketplace prescription drug plans in 2024, while 82% covered Ozempic, which has the same active ingredient but is approved for diabetes. Every Marketplace plan that covered obesity-approved GLP-1 drugs required prior authorization. In Medicaid, obesity coverage is optional for states, and as of January 2026 only 13 state Medicaid programs covered GLP-1 drugs for obesity treatment under fee-for-service.

Federal policy has not closed the gap. KFF said the Trump administration did not move ahead with a Biden-era proposal that would have allowed Medicare and required Medicaid to cover obesity drugs, even as new coverage initiatives have begun. That leaves the rules split across employers, Medicaid, Medicare and Marketplace plans, with patients treated very differently depending on where they get insurance.

The strain is already showing in Washington, where UnitedHealth said on April 21 that there were "challenges" around the Medicare obesity-drug pilot. CVS Health declined to participate in the program, underscoring how resistant major insurers remain as policymakers look for a way to broaden access. A White House deal with Novo Nordisk and Eli Lilly is also intended to cap GLP-1 prices at no more than $350 a month for some patients, but for now the coverage retreat is widening the divide between people who can keep taking the drugs and those who cannot.